Provider Network Notification

Genetic Testing for BRCA1/BRCA2 Mutations

August 2021

OVERVIEW:

Aetna Better Health of Louisiana (ABHLA) is aligned with the Louisiana Department of Health's Medicaid Services Manual, and would like to remind providers to refer to these manuals when submitting claims. If the manual requires additional guidance impacting reimbursement, the details will be outlined by ABHLA in the Provider Manual or in a supporting reimbursement policy.

In alignment with the Louisiana Medicaid Professional Services Manual, genetic testing for BRCA1 and BRCA2 mutations in cancer-affected and cancer-unaffected individuals is considered medically necessary when the beneficiary:

- Has any blood relative with a known BRCA1/BRCA2 mutation
- Meets the criterial below but with previous, limited testing (eg, single gene and/or absent deletion duplication analysis) interested in pursuing multi-gene testing
- Has a personal history of cancer, defined as one of more of the following:
    - Breast cancer and one or more of the following:
        - Diagnosed at age 45 or younger, or
        - Diagnosed at age 45—50 with:
            - Unknown or limited family history; or
            - A second breast cancer diagnosed at any age; or
            - At least one close blood relative with breast, ovarian, pancreatic, or high-grade (Gleason score of at least 7) or intraductal prostate cancer at any age
        - Diagnosed with triple negative breast cancer at age 60 or younger;
        - Diagnosed at any age with:
            - Ashkenazi Jewish ancestry; or
            - At least one close blood relative with breast cancer at under 50 years of age or ovarian, pancreatic, or metastatic or intraductal prostate cancer at any age; or
            - At least three total diagnoses of breast cancer in patient and/or close blood relatives
        - Diagnosed at any age with male breast cancer; or
        - Epithelial ovarian cancer (including fallopian tube cancer or peritoneal cancer) at any age;
    - Exocrine pancreatic cancer at any age;
    - Metastatic or intraductal prostate cancer at any age;
    - High-grade (Gleason score at least 7) prostate cancer at any age with:

        - Ashkenazi Jewish ancestry; or
        - At least one close blood relative with breast cancer diagnosed at age 50 or younger, or ovarian, pancreatic, or metastatic or intraductal prostate cancer at any age; or
        - At least two close blood relatives with breast or prostate cancer (any grade) at any age
    - A mutation identified on tumor genomic testing that has clinical implications if also identified in the germline
    - To aid in systemic therapy decision-making, such as for HER2-negative metastatic breast cancer
- Has a family history of cancer, including unaffected individuals defined one or more of the following:
    - An affected or unaffected individual with a 1st- or 2nd-degree blood relative meeting any of the criterion listed above (except individuals who meet criteria only for systemic therapy decision-making); or
    - An affected or unaffected individual who otherwise does not met criteria above but also has a probability >5% of a BRCA1/2 pathogenic variant based on prior probability models (eg, Tyer-Cuzick, BRCAPro, Pennll)

Genetic testing in individuals not meeting the above criteria is considered not medically necessary and are not covered.

The following CPT Codes for BRCA1 and BRCA2 genetic testing are covered where medically necessary: 81162 – 81167, 81212, 81215 - 81217

Claims for the above genetic testing services for Members under 19 years of age are not covered and may be denied.

Please note that providers may see reimbursement impacted if not aligned to the Louisiana Department of Health's Medicaid services manual within 30 days of the date of this reminder notification.

Questions and Support:

For questions, please contact LAProvider@AETNA.com or call 1-855-242-0802 and follow the prompts.